Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03808376 · ClinicalTrials.gov registry record · NA
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
A NA study, sponsored by Senseonics.
- Completed
- Registry status
- NA
- Development phase
- 208
- Enrollment target
NCT03808376 is a NA study that has completed, run by Senseonics. The registered enrollment target is 208 participants.
The verdict
NCT03808376, a NA study, has completed, sponsored by Senseonics.
- COMPLETED
- Registry status
- NA
- Development phase
- 208 participants
- Enrollment target
Study Summary
The purpose of this clinical investigation is to evaluate the accuracy of the Eversense® continuous Glucose Monitoring System (Eversense® 180 CGM System) measurements when compared with reference standard measurements up to 180 days of sensor use. The investigation will also evaluate safety of the Eversense® 180 CGM System usage.
Interventions
- DEVICE Continuous Glucose Monitoring System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2020-05-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03808376
The ClinicalTrials.gov registry entry for NCT03808376 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senseonics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitoring System is the first listed.
NCT03808376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03808376 about?
NCT03808376 is a clinical study titled "PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days". The purpose of this clinical investigation is to evaluate the accuracy of the Eversense® continuous Glucose Monitoring System (Eversense® 180 CGM System) measurements when compared with reference standard measurements up to 180 days of sensor use. The investigation will also evaluate safety of the ...
What is the current status of trial NCT03808376?
This trial is currently completed. It is a NA study. The enrollment target is 208 participants. The study started on 2018-12-27. Estimated completion is 2020-05-08.
What interventions are being tested in trial NCT03808376?
The interventions under investigation include: Continuous Glucose Monitoring System (DEVICE).
Who is sponsoring clinical trial NCT03808376?
This trial is sponsored by Senseonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.